Isofol Completes Share Transfer to Solasia Pharma, Strengthening Partnership

The latest update is out from Isofol Medical AB ( (SE:ISOFOL) ).

Isofol Medical AB has successfully completed the transfer of shares to its Japanese partner, Solasia Pharma, following an oversubscribed rights issue. This investment by Solasia Pharma underscores their commitment to the development of Isofol’s drug candidate, arfolitixorin, and strengthens their strategic partnership, particularly for advancing the drug’s presence in the Japanese market.

More about Isofol Medical AB

Isofol Medical AB is a biotechnology company focused on improving treatments for severe forms of cancer. Their primary drug candidate, arfolitixorin, is designed to enhance the effectiveness of first-line treatments for solid tumors, particularly in colorectal cancer, which is the third most common cancer globally. The company is publicly traded on Nasdaq Stockholm.

Average Trading Volume: 1,121,409

Technical Sentiment Signal: Strong Sell

Current Market Cap: SEK227.7M

Find detailed analytics on ISOFOL stock on TipRanks’ Stock Analysis page.